<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03911271</url>
  </required_header>
  <id_info>
    <org_study_id>Line Kessel, RH-Glostrup</org_study_id>
    <nct_id>NCT03911271</nct_id>
  </id_info>
  <brief_title>Low-dose Atropine for the Prevention of Myopia Progression in Danish Children</brief_title>
  <acronym>APP</acronym>
  <official_title>Low-dose Atropine for the Prevention of Myopia Progression in Danish Children - a Randomized, Double-masked, Multicenter, 36-month Prospective 1:1:1 Study of Safety and Efficacy of 0.1% Atropine Loading Dose to Single 0.01% Atropine and Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Line Kessel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myopia (nearsightedness) is increasing in prevalence throughout the world. It is associated
      with a risk of potentially blinding complications such as retinal detachment and myopic
      maculopathy. There is a direct association between the degree of myopia and the risk of
      complications. Myopia develops in childhood and during adolescence. To prevent higher degrees
      of myopia, we need to halt disease progression in children and teenagers. Low-dose atropine
      eye drops have been shown to reduce myopia progression by 50% in Asian populations but its
      effect in non-Asian populations is unknown. The aim of this study is to investigate if
      low-dose atropine can reduce myopia progression in Danish children and teenagers. The study
      is an investigator initiated randomized clinical trial conducted as a collaboration between
      three Danish Eye Departments covering all of Denmark.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main hypotheses tested in this study are:

        -  0.01% atropine one drop nightly reduces the progression of childhood myopia in Danish
           children.

        -  0.01% atropine one drop nightly is safe and with no significant side effects.

        -  A 6-month loading dose of 0.1% atropine followed by a 0.01% atropine maintenance dose is
           superior to single 0.01% atropine.

        -  0.1% atropine one drop nightly is safe and has tolerable side effects.

        -  The rebound effect after stopping both atropine regimens is limited.

        -  Choroidal thickness is a predictor for the progression of childhood myopia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in axial length</measure>
    <time_frame>36 months</time_frame>
    <description>Treatment group comparison of change in axial length elongation from baseline to 36 months, as measured using IOLMaster 700</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in spherical equivalent</measure>
    <time_frame>36 months</time_frame>
    <description>Treatment group comparison of change in spherical equivalent from baseline to 36 months, as measured using cycloplegic autorefraction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects and reactions</measure>
    <time_frame>36 months</time_frame>
    <description>Treatment group comparison of adverse effects and reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in choroidal thickness</measure>
    <time_frame>36 months</time_frame>
    <description>Treatment group comparison of change in choroidal thickness from baseline to 36 months, as measured using optical coherence tomography (OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ocular biometry</measure>
    <time_frame>36 months</time_frame>
    <description>Treatment group comparison of change in ocular biometry (i.e. keratometry, anterior chamber depth, lens thickness, vitreous axial distance) from baseline to 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in higher-order aberrations</measure>
    <time_frame>36 months</time_frame>
    <description>Treatment group comparison of change in higher-order aberrations from baseline to 36 months</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Loading dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In phase 1 (treatment phase), the participants (n=50) will receive 0.1% atropine loading dose for 6 months followed by 0.01 % atropine for 18 months. The eye drops are administered as one eye drop daily in each eye at bedtime.
In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In phase 1 (treatment phase), the participants (n=50) will receive 0.01 % atropine for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime.
In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In phase 1 (treatment phase), the participants (n=50) will receive placebo eye drops for 24 months. The eye drops are administered as one eye drop daily in each eye at bedtime.
In phase 2 (washout phase), treatment will be stopped and the participants monitored for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1% atropine and 0.01% atropine</intervention_name>
    <description>0.1% atropine loading dose for 6 months followed by 0.01% atropine for 18 months</description>
    <arm_group_label>Loading dose</arm_group_label>
    <other_name>Loading dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.01% atropine</intervention_name>
    <description>0.01% atropine for 24 months</description>
    <arm_group_label>Low dose</arm_group_label>
    <other_name>Low-dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Sodium-chloride</intervention_name>
    <description>Placebo for 24 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children aged ≥6-&lt;9 years: myopia ≤-1 (spherical power) in at least one eye

          -  Children aged ≥9-≤12 years: myopia ≤-2 (spherical power) in at least one eye

          -  Cylinder less than 1.5 diopters

        Exclusion Criteria:

          -  Myopia related to retinal dystrophies

          -  Collagen syndroms (Ehlers-Danlos syndrome, Marfan syndrome and Stickler syndrome)

          -  Other ocular pathology (e.g., amblyopia, strabismus)

          -  Previous eye surgery

          -  Previous use of agents thought to affect myopia progression, e.g. atropine,
             pirenzepine or 7-methylxanthine (metabolite of caffeine and theobromine) and
             orthokeratology contact lenses

          -  Known allergy to atropine or any of the contents of the trial medication (active and
             in-active ingredients) used in the study

          -  Non-compliance to eye examinations

          -  Serious systemic health troubles (e.g., cardiac or respiratory illness) and
             developmental disorders and delays
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anders Hvid-Hansen, MD</last_name>
    <phone>0045 3863 4750</phone>
    <email>anders.johan.hvid-hansen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Line Kessel, MD, Ph.D.</last_name>
    <phone>0045 3863 4132</phone>
    <email>line.kessel.01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Ophthalmology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Toke Bek, Prof., DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesper Hjortdal, Prof., DMSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dorte Larsen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology, Rigshospitalet-Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Line Kessel, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>NIna Jacobsen, MD, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anders Hvid-Hansen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Flemming Møller, MD, DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bettina Lehrmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fifa Björnsson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Line Kessel</investigator_full_name>
    <investigator_title>Consultant ophthalmologist, Associate Professor, MD, Ph.D., FEBO</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

